George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Geowiz: your take n this bit? For me, probably the best section of the rns…
Except for deliberate shut-in periods to monitor pressure build-up, the well has flowed naturally since 16 January 2022. At larger choke sizes, the well has flowed at higher gas rates than that stated above. Currently, production rates are being constrained to stay within the safe operating limits of the existing gas infrastructure.
Or take the risk with that last 10% that the project will come to a successful conclusion with NCCL having a 40% share…
We all make our choices Stan, and you have chosen not to invest…but thanks for providing us with your risk assessment.
To the rescue?
Appears to me to be a sensible outcome provided the main project still gets completed.
Glah
Charliebucket…
Dildo?
Fair enough Stan. We all try to do what we believe will best accumulate/preserve capital, but the cesspit that is AIM is always a huge gamble….
Atb
So your “sells galore today” from a week ago ( totalling 7k shares) works in a different ecomnomic universe to that buy? .
“ 820k shares is only £10k , big deal”
All you words.
Just keeping it real….
Not happy with the co, but I don’t think we really need any comments from your good self.
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces that it has signed a Head of Terms ("HOT") partnership agreement with DAM Health Limited ("DAM Health"), a leader in fit-to-fly testing and one of the UK's fastest growing and largest in-clinic and mobile test providers for COVID-19. Under the agreement, Omega will exclusively supply its VISITECT® professional use COVID-19 Antigen tests ("LFT") to DAM Health's clinics throughout the UK and Europe. Omega has already received an initial purchase order in excess of £750,000 to supply VISITECT® professional use COVID-19 antigen tests to DAM Health.
With COVID-19 cases surging again and PCR requirements being replaced with Antigen LFTs, this partnership, which is for an initial period of 12-months, sees two innovative and pioneering UK companies combining their expertise and knowledge as we learn to live with COVID-19. Manufactured in the UK, a recent 2021 study by FIND Diagnostics1, a leading testing authority in Geneva, Switzerland, found the VISITECT® test delivered results of 100% in specificity and 96.4% in sensitivity. Under the agreement, DAM Health agrees to exclusively use, sell and promote Omega's test throughout its network of over 100 clinics in the UK and Europe. DAM Health is currently using approximately 200,000 in-clinic COVID tests per month.
Whilst the initial agreement centers around the VISITECT® professional Antigen LFTs, there is the possibility to broaden the partnership to include Omega's VISITECT® antigen self-test LFT (once approved) and for DAM Health to sell Omega's Food Detective product throughout its network. There is also provision to extend this relationship beyond Europe, as DAM Health expand their international network of clinics globally. A further update will be provided on this in due course.
Additionally, this agreement with DAM Health allows Omega to honour its existing contractual commitments with the Department of Health and Social Care ("DHSC"). Omega still awaits a decision from DHSC as to which COVID-19 test the Company will manufacture.
Colin King, CEO, Omega Diagnostics, said: "We have been actively seeking commercial partners for our COVID-19 antigen tests with the support of Lansdown Strategic Capital. We are delighted to be to be utilising some of our lateral flow test production capacity and to be working with DAM Health, who are leaders in the space. Reaching a commercial agreement with a leading and fast-growing testing provider is a major milestone for the Company in bringing our gold-standard test to market and we look forward to working collaboratively with DAM Health and are hopeful that this partnership can be broadened to cover more of Omega's products, not just in the COVID space."
Sells Galore?
Must be seeing different data…..three trades for a total of less than £7k?
You must be a riot on the open mic comedy nights….
I really wish I could agree with those stats Regulator, but stats can show what you want them to…
Like many I’m a believer in testing, but until the Govt start reporting figures as “From” not “With” covid, we have no real idea what the genuine impact of covid is.
And no, Im definitely not anti…missus works high level T&T and has spoken to and supported people who have lost close relatives FROM covid, but you know the rest of the argument re: previously terminal patients….
But thereis a clue…
“ previous sucker rod pump was functioning at only 20% capacity and that the well did not have a tubing hanger installed, in contradiction of the 2012 well report.”
Allow for not achieving 100%, indication would be 80+bopd
Onwards &upwards
According to the Barclays guy I spoke to (yes, you have to call and vote), they dont register the proxies until 2 days before the resolution.
So anyone who voted against via Barclays is likely to be invisible to the BOD until tomorrow of friday.
I wonder if this RNS is a final attempt to get more PIs voting against because they aren’t sure of the win yet.
So, if you havent already done it…..Vote Against
GLA
Wonder if the funding will be sorted by a transfer of interest in the finished project to CMEC?
Im sure they can find the cash, but it might not be our best option?
Zenith Energy Ltd. ("Zenith" or the "Company") (LSE: ZEN; OSE: ZENA), the listed international oil & gas production company focused on pursuing African development opportunities, is pleased to announce that one of its fully owned subsidiaries in the Republic of the Congo, Anglo African Oil & Gas Congo S.A.U. ("AAOG Congo"), has received a payment for an amount of approximately US$128,000, in respect of past oil production produced during the now expired Tilapia I licence by AAOG Congo from Congolaise de Raffinage ("CORAF"), a subsidiary of the national oil company of the Republic of the Congo, Société Nationale des Pétroles du Congo ("SNPC").
The Company is pleased to have received this payment which it views as clear evidence of the Company's ability to successfully monetise receivables it is owed in Republic of the Congo.
….not bad when you consider the fact that we paid £200k for the licence. Onwards and upwards.
If I may add, SEA7, and it can’t be highlighted enough for THIS resolution…
“ That the board of the directors of the Company (the "Board") commission an independent forensic investigation into the affairs of the Company which will:”
Leaves the financing with the company, not with the cabal….
Voted against.
If they wish to change the resolution, I would vote differently.
Iirc there is another entity that goes the the name of Lionsgold?
Any refs to us at that date would surely use Tally?